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S242 Poster Session Ireducing HLH related immunopathology, this strategy leads to pro-
found iatrogenic marrow and immune suppression, thus greatly in-
creasing the risk of opportunistic infection. With the explosion of
cinically available immunosuppressive agents, there is a critical
need to define which sorts of immune suppression offer the most ef-
fective yet focused treatment for HLH.
In this study, we utilize our animal model of HLH as a preclinical
screen to test the effectiveness of targeted immune suppression using
agents that interfere with interleukin-2 production or signal trans-
duction in T cells. LCMV-infected prf-/- mice experience exagger-
ated symptomaticity, massive elevations in serum IFNg, and
consumptive anemia before becoming moribund. When these mice
are treated with the mTOR inhibitor rapamycin, either alone or in
combination with inhibitors of T cell costimulation (CTLA4-Ig or
anti-CD2), they show improvements in disease severity, survival,
and hemoglobin levels similar to the benefit seen in animals treated
with etoposide monotherapy. We will present data showing the ef-
fects of these agents on the activation of dendritic cells, T cells,
and macrophages in the context of our animal model.226
OUTCOMES AFTER ADDITION OF RABBIT-ATG TO THE STANDARD
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(HSCT) FOR HEMOGLOBINOPATHIES IN CHILDREN
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Introduction: Allogeneic HSCT for hemoglobinopathies following
myeloablative conditioning in MSD setting results in excellent out-
comes in children (85-95% 5 year EFS). Though outcomes are en-
couraging, there is still a 7%-10% incidence of graft rejection and
15-20% incidence of GVHD.We proposed the hypotheses, that ad-
ministration of 10 mg/kg dose of rabbit-ATG (Thymoglobulin,
Genzyme, Cambridge, USA) during the peri-transplant period for
MSDHSCT,will lead to partial in-vivoT-cell depletion; eliminating
the risk of rejection andGVHDwhile not increasing the risk of infec-
tions.
Methods: Patients with sickle cell disease (SCD) with sequelae and
transfusion dependent b-thalassemia, underwentMSDHSCT on an
IRB approved study starting Jan, 2003. All patients received iv Busul-
fan (16 mg/kg over 4 days; targeted AUC of 900-1350 mM/mt, based
on 1st dose PK); Cyclophosphamide (50 mg/kg 4 days) and r-ATG
(2.5 mg/kg/day from days -6 to -3). Cyclosporine and standard short
course Methotrexate on days +1, +3 and +6 was given for GVHD
prophylaxis.
Results: 11 patients (9 SCD and 2 b-Thalassemia; 6 females and 5
males) have received the preparative regimen. Median age of patients’
was 4 years (range,18 months-18 years). The r-ATG infusions were
well tolerated with no missed doses. All patients received sibling BM
grafts with the median cell dose of 3.5  108 TNC/kg (range, 1.8-
10.1  108 TNC/kg). All patients developed grade II-III mucositis.
One patient developedmild VOD and one patient had seizures associ-
ated with reversible posterior leuco-encephalopathy syndrome. All pa-
tients engrafted (ANC.0.5 109/L) bymedianof day +15 (range, day
+10 to +23). 2 patients developedCMVreactivations that responded to
treatment. No other viral reactivations or fungal infections were de-
tected. Serial chimerism analysis post-HSCT shows stable donor en-
graftment in all patients. There was no TRM and none of the
patients developed acute GVHD. One patient developed limited
chronic GVHD of the skin. EFS is 100% after a median follow up of
404 days (range, 61-2409 days) with complete resolution of underlying
disease. End organ function is stable and immune reconstitution is
complete in all the patients evaluable.1 year post-HSCT.
Conclusions:Addition of 10 mg/kg dose of rabbit-ATG to the stan-
dard Bu + CYmyeloablative regimen has minimized the incidence of
rejection, acute and chronic GVHD without increasing toxicity or
incidence of infections for MSD HSCT for hemoglobinopathies.227
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Although BMT plays an important role in the therapy of ALL, the
outcome of children transplanted in third remission (CR3) is poorly
defined. We reviewed 155 children, median age 11 years (range, 1-
18), who received an unrelated donor BMT for ALL in CR3 from
1990 to 2005. Median time from diagnosis to first relapse was 35
months, and median time from first to second relapse was 26 months
(range, 4-116). Stem cell sources were bone marrow (n5 115), pe-
ripheral blood stem cells, PBSC (n5 11) or cord blood (n5 29).
BM and PBSC donor-recipient pairs (n5 126) were matched at
HLA-A, B, C and DRB1 (n5 40, 32%), or mismatched at either
one locus (n5 36, 28%) or$ 2 loci (n5 50, 40%). Cord blood do-
nor-recipient pairs (n5 29) were matched at HLA-A, B, DRB1
(n5 1) or mismatched at either one locus (n5 6) or 2 loci
(n5 22). 92% of patients received total-body irradiation (TBI) and
42% received TBI dose .1300 cGy. Graft vs. host disease
(GVHD) prophylaxis was cyclosporine or tacrolimus plus another
agent in 63% of patients. 31% of patients received T-cell depleted
BM grafts and 52% received ATG as part of transplant conditioning
regimen. The cumulative incidence of neutrophil recovery was 95%
(95% CI, 95- 98%). The day-100 cumulative incidence of grade 2-4
acute GVHD was 58% (50-66%) and chronic GVHD at 3-years,
28% (95% CI 21-35%). The risk of chronic GVHD higher in
PBSC recipients (RR 2.85, 95% CI1.18-6.92, p5 0.01). The inci-
dence of non-relapse mortality (NRM) was 19% (95% CI 14-
26%) at 100 days, 41% (95% CI 33-49%) at 1-year and 45% (95%
CI 37-53%) at 5-years. Causes of NRM included graft failure
(2%), GVHD (5%), infection (12%), organ toxicity (21%), second-
ary malignancies (3%) and other causes (6%). 47 patients are alive at
last follow-up, with median follow-up of 6 years. In multivariate
analysis, the interval between first and second relapse was associated
with relapse after BMT. Relapse risks were higher in patients for
whom this interval was #26 months (RR 2.50, 95% CI 1.28-4.76,
p5 0.01). No risk factors were identified for non-relapse mortality.
The 5-year cumulative incidence of relapse was 17% (95% CI 9-
26%) and 34% (95% CI 24-45%) in patients with a second relapse
.26 months and #26 months from their first relapse, respectively.
Corresponding 5-year leukemia-free survival rates were 33% (95%
CI 23-44%) and 26% (95% CI 16-36%). Unrelated donor BMT re-
sults in acceptable disease free-survival in children with ALL in CR3,
especially those experiencing a late second relapse.228
REDUCED INTENSITY CONDITIONING (RIC) WITH FLU-BU-ATG AND AL-
LOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
FROM HLA IDENTICAL DONORS: RELAPSE-FREE SURVIVAL (RFS) OF
42% IN PEDIATRIC PATIENTS WITH HIGH-RISK HEMATOLOGIC MALIG-
NANCIES
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RIC regimens prior to allogeneic HSCT diminish potential com-
plications compared with myeloablative therapy. We report the ex-
perience of 31 RIC HSCT for children/adolescents with
hematologic malignancies at high-risk for relapse or complications
of full-intensity conditioning due to disease state, prior myeloabla-
tive HSCT and/or co-morbid conditions. The RIC regimen was
comprised of fludarabine, 180 mg/m2 over 6 days, 2 days of IV bu-
sulfan; and 4 days of ATG (equine or rabbit). Diagnoses included:
ALL (14, $CR3 in 7), AML (5), treatment-related myelodysplastic
